Sino Biopharmaceutical’s IDH1 Inhibitor TQB3454 Receives NMPA Priority Review for Biliary Tract Cancer

Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd. (HKG: 1177), announced that its Category 1 drug TQB3454 has been granted priority review status by the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA). The filing seeks approval for locally advanced, recurrent, and/or metastatic biliary tract cancer (BTC) harboring IDH1 mutations in patients who have failed prior gemcitabine- and fluorouracil-based regimens.

Regulatory Milestone & Clinical Validation

Drug Mechanism & Scientific Rationale

• Target: Mutant IDH1 enzymes specifically
• Mechanism of Action:
• Reduces downstream 2-hydroxyglutarate (2-HG) levels
• Reverses DNA and histone hypermethylation caused by elevated 2-HG
• Restores normal chromatin structure
• Promotes proper cellular differentiation and developmental processes
• Therapeutic Effect: Anti-malignant activity through epigenetic reprogramming of mutant cells

Pivotal Phase III Clinical Results

TQB3454-III-01 Study (March 2026 Interim Analysis)

Market Opportunity & Therapeutic Context

Biliary Tract Cancer Landscape

• Incidence: Approximately 8,000-10,000 new BTC cases annually in China
• IDH1 Mutation Prevalence: 10-20% of intrahepatic cholangiocarcinoma cases
• Current Treatment Limitations: Limited effective options after first-line chemotherapy failure
• Survival Outcomes: Median OS typically <12 months in refractory setting

Competitive IDH1 Inhibitor Landscape

Strategic Implications

For Sino Biopharmaceutical/CTTQ

• Precision Medicine Leadership: Establishes position in genetically targeted oncology therapies
• Commercial Advantage: Priority review accelerates time to market in underserved indication
• Pricing Power: Category 1 designation supports premium pricing in China
• Global Potential: Positive Phase III data could support international regulatory filings

China Oncology Market Dynamics

• Precision Medicine Adoption: Increasing acceptance of biomarker-driven treatment approaches
• Healthcare Policy Support: Government prioritizes domestic innovative drugs for rare mutations
• Reimbursement Pathway: Priority review often correlates with faster inclusion in national reimbursement drug list (NRDL)
• Physician Education: Need for increased IDH1 testing adoption in BTC clinical practice

Development Timeline & Commercial Outlook

• NMPA Decision Expected: Q4 2026 – Q1 2027 (accelerated by priority review)
• Market Launch: Anticipated H1 2027
• Companion Diagnostic: Likely co-development with IDH1 mutation testing platforms
• Revenue Potential: Estimated ¥500-800 million annual peak sales in China BTC market

Forward-Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, clinical development, and commercial potential for TQB3454. Actual results may differ due to risks including final NMPA approval decisions, market competition, companion diagnostic development, and evolving treatment guidelines for biliary tract cancer.-Fineline Info & Tech